Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours
Jan Meiners,
Kristina Jansen,
Natalia Gorbokon,
Franziska Büscheck,
Andreas M. Luebke,
Martina Kluth,
Claudia Hube-Magg,
Doris Höflmayer,
Sören Weidemann,
Christoph Fraune,
Katharina Möller,
Christian Bernreuther,
Patrick Lebok,
Anne Menz,
Frank Jacobsen,
Till Clauditz,
Guido Sauter,
Ria Uhlig,
Waldemar Wilczak,
Jakob Izbicki,
Daniel Perez,
Sarah Minner,
Eike Burandt,
Till Krech,
Andreas Marx,
Ronald Simon,
Stefan Steurer
Affiliations
Jan Meiners
General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Kristina Jansen
General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Natalia Gorbokon
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Franziska Büscheck
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Andreas M. Luebke
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Martina Kluth
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Claudia Hube-Magg
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Doris Höflmayer
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Sören Weidemann
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Christoph Fraune
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Katharina Möller
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Christian Bernreuther
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Patrick Lebok
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Anne Menz
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Frank Jacobsen
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Till Clauditz
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Guido Sauter
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Ria Uhlig
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Waldemar Wilczak
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Jakob Izbicki
General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Daniel Perez
General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Sarah Minner
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Eike Burandt
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Till Krech
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Andreas Marx
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Ronald Simon
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Stefan Steurer
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Angiotensin-converting enzyme 2 (ACE2) is a regulator in the renin-angiotensin system. ACE2 expression was analysed immunohistochemically in 15,306 samples from 119 tumour types and in 608 samples of 76 normal tissue types. In normal tissue, ACE2 was most abundant in testis and corpus luteum, kidney, small intestine and capillaries of selected organs. At least an occasional weak ACE2 positivity of tumour cells was seen in 83 of 119 (70%) tumour types. ACE2 tumour cell positivity was particularly frequent in papillary (94%) and clear cell (86%) renal cell carcinoma, colorectal adenocarcinoma (81%), mucinous ovarian cancer (61%), cholangiocarcinoma (58%), hepatocellular carcinoma (56%), and in adenocarcinomas of the stomach (47%), pancreas (42%), and the lung (35%). ACE2-positive capillaries were found in 409/12,644 (3%) of analysable tumours, most frequently in tumours with endocrine/neuroendocrine activity. Presence of ACE2-positive capillaries was linked to low stage in papillary thyroid cancer and low grade in neuroendocrine neoplasms. In conclusion, ACE2 expression can occur both in tumour cells and tumour-associated capillaries in a broad variety of different tumour types at highly variable frequencies.